Key Highlights
- Vyome Holdings (NASDAQ:HIND) reported a nine-month net loss of USD 2,635,529 for 2026, against USD 9,198,033 a year earlier, or USD 0.37 per share against USD 9.82.
- Nine-month Research and Development spending rose to USD 1,582,959 from USD 210,006, driven by regulatory consulting and Manufacturing preparation work for the lead program, VT-1953.
- Cash and cash equivalents stood at USD 6,956,822 on September 30, 2026, up from USD 4,982,333 at the end of 2025, helped by USD 5,285,868 raised through an ATM facility.
- Third-quarter Revenue was USD 57,998 against USD 34,627, while the third-quarter net loss narrowed to USD 930,325 from USD 8,595,300.
Prior-Year Merger Costs Drop Out of the Loss
Vyome Holdings (NASDAQ:HIND), formerly ReShape Lifesciences, filed its Quarterly Report on November 12, 2026, for the quarter ended September 30, 2026. The company describes itself as a clinical-stage specialty pharmaceutical Business based in Cambridge, Massachusetts, Princeton, New Jersey, and New Delhi, working on treatments for immune-inflammatory and rare diseases. For the nine months, the net loss was USD 2,635,529 against USD 9,198,033, a decline of about 71.3% on a calculated basis. The prior-year period carried USD 7,705,533 of transaction fees tied to the merger, and no such charge appears in 2026. Interest income and other items added USD 387,223 this year, and the company reports in whole dollars, so the figures here are exact amounts.
VT-1953 Work Lifts Research Spending
Research and development spending reached USD 1,582,959 for the nine months, up from USD 210,006, and USD 409,831 in the third quarter against USD 39,677. The report attributes the rise to regulatory consulting and manufacturing preparation for VT-1953, a topical gel being developed for signs and symptoms of malignant fungating wounds. The company has received pre-investigational new drug feedback from the FDA and plans a Type C meeting, and it filed an Orphan Drug designation application in January 2026. Selling, general and administrative costs were USD 1,477,876 against USD 1,369,365. Nine-month revenue from its legacy antifungal products fell to USD 116,544 from USD 283,163, while third-quarter revenue rose to USD 57,998 from USD 34,627.
ATM Proceeds Support a 15-Month Cash Horizon
Cash and cash equivalents were USD 6,956,822, and total current Assets were USD 7,598,424. Proceeds from selling common stock under the ATM Facility were USD 5,285,868 in the nine months, against USD 679,633 a year earlier. Management believes existing cash, including merger-related financing and ATM sales to date, can fund operating needs for at least 15 months, including the start of a pivotal trial of VT-1953, though not its completion. The filing also carries a Going Concern note, which says further financing is needed and may not be available on acceptable terms. The company disclosed that its disclosure controls were not effective because of material weaknesses, and a goods and services tax dispute in India carries a Demand of about USD 739,000. As of November 9, 2026, there were 7,018,528 shares outstanding.
Where Things Stand
Vyome Holdings (NASDAQ:HIND) cut its nine-month loss to USD 2.6 million largely because USD 7.7 million of merger transaction fees from the prior year did not repeat, not because the underlying business grew. Spending on VT-1953 is rising, revenue remains below USD 120,000 for the period, and cash of USD 6.96 million is supported by ATM sales. The points to watch are the FDA Type C meeting, the orphan drug designation decision, further use of the ATM facility, the Indian tax dispute and the going concern language.


_11_18_2026_14_48_04_195267.jpg)



Please wait processing your request...